Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Leonel Gallegos"'
Autor:
Roland B. Walter, Bruno C. Medeiros, Kelda M. Gardner, Kaysey F. Orlowski, Leonel Gallegos, Bart L. Scott, Paul C. Hendrie, Elihu H. Estey
Publikováno v:
Haematologica, Vol 99, Iss 1 (2014)
Epigenetic therapeutics such as the histone deacetylase inhibitor, vorinostat, and the DNA methyltransferase I inhibitor, azacitidine, enhance gemtuzumab ozogamicin efficacy in vitro. We therefore investigated vorinostat/azacitidine/gemtuzumab ozogam
Externí odkaz:
https://doaj.org/article/a48e037ac1f5450fa9441987e9993b83
Autor:
Daniel A. Pollyea, James Zehnder, Steve Coutre, Jason R. Gotlib, Leonel Gallegos, Omar Abdel-Wahab, Peter Greenberg, Bing Zhang, Michaela Liedtke, Caroline Berube, Ross Levine, Beverly S. Mitchell, Bruno C. Medeiros
Publikováno v:
Haematologica, Vol 98, Iss 4 (2013)
There are limited treatment options for older patients with acute myeloid leukemia and prognosis of these patients remains poor, thereby warranting development of novel therapies. We evaluated the efficacy and safety of azacitidine in combination wit
Externí odkaz:
https://doaj.org/article/15622216c8d5410ab4a8c26baf02fc80
Autor:
Bruno C. Medeiros, Bart L. Scott, Kaysey F. Orlowski, Kelda M. Gardner, Paul C. Hendrie, Roland B. Walter, Leonel Gallegos, Elihu H. Estey
Publikováno v:
Haematologica. 99:54-59
Epigenetic therapeutics such as the histone deacetylase inhibitor, vorinostat, and the DNA methyltransferase I inhibitor, azacitidine, enhance gemtuzumab ozogamicin efficacy in vitro. We therefore investigated vorinostat/azacitidine/gemtuzumab ozogam
Autor:
James L. Zehnder, Bruno C. Medeiros, Omar Abdel-Wahab, S. E. Coutre, Caroline Berube, Peter L. Greenberg, Daniel A. Pollyea, Bing Zhang, Leonel Gallegos, Jason Gotlib, Beverly S. Mitchell, Ross L. Levine, Michaela Liedtke
Publikováno v:
Haematologica. 98:591-596
There are limited treatment options for older patients with acute myeloid leukemia and prognosis of these patients remains poor, thereby warranting development of novel therapies. We evaluated the efficacy and safety of azacitidine in combination wit
Autor:
James L. Zehnder, Steven Coutre, S Bhattacharya, Ross L. Levine, Caroline Berube, Daniel A. Pollyea, Beverly S. Mitchell, Leonel Gallegos, Ari Melnick, Bing Zhang, Bruno C. Medeiros, Maria E. Figueroa, Omar Abdel-Wahab, Holbrook E Kohrt, Jason Gotlib, Michaela Liedtke
Publikováno v:
Leukemia. 26:893-901
Acute myeloid leukemia (AML) is a disease of the elderly. Poor outcomes with standard therapies necessitate novel approaches. Outpatient regimens sufficiently potent and well tolerated to induce remissions and enable continuation therapy may be benef
Autor:
Paul C. Hendrie, Kelda M. Gardner, Kaysey F. Orlowski, Elihu H. Estey, Roland B. Walter, Leonel Gallegos, Bruno C. Medeiros, Bart L. Scott
Publikováno v:
Blood. 122:3936-3936
Background Epigenetic therapeutics such as the histone deacetylase (HDAC) inhibitor, vorinostat, and the DNA methyltransferase (DNMT) I inhibitor, azacitidine, sensitize AML cells in vitro to the CD33-targeting immunoconjugate, gemtuzumab ozogamicin
Autor:
Jason Gotlib, Leonel Gallegos, Peter L. Greenberg, Bruno C. Medeiros, Daniel A. Pollyea, Bing Zhang, Michaela Liedtke, Ross L. Levine, James L. Zehnder, Steven Coutre
Publikováno v:
Blood. 120:3575-3575
Abstract 3575 There are limited treatment options for older patients with acute myeloid leukemia (AML) and prognosis has remained poor, thereby warranting development of novel therapeutic strategies. The optimal treatment for these patients requires
Autor:
Maria E. Figueroa, Michaela Liedtke, James L. Zehnder, Beverly S. Mitchell, Jason Gotlib, Bruno C. Medeiros, Bing Zhang, Ari Melnick, Leonel Gallegos, Caroline Berube, S. E. Coutre, Daniel A. Pollyea, Holbrook E Kohrt
Publikováno v:
Journal of Clinical Oncology. 29:6505-6505
6505 Background: Most AML patients (pts) are elderly with poor outcomes, correlating with tumor suppressor gene (TSG) hypermethylation. Azacitidine (AZA) demethylates TSGs; lenalidomide (LEN) has anti-leukemia activity. We hypothesize this combinatio
Autor:
Holbrook E Kohrt, Beverly S. Mitchell, Bruno C. Medeiros, Michaela Liedtke, Jason Gotlib, Daniel A. Pollyea, Steven Coutre, Leonel Gallegos, Caroline Berube
Publikováno v:
Blood. 116:3288-3288
Abstract 3288 Introduction: The elderly constitute the majority of patients (pts) with AML. Effective and tolerable therapeutic alternatives are necessary for these pts, in whom outcomes with standard induction therapy are poor. Azacitidine (AZA), a
Autor:
Michaela Liedtke, Beverly S. Mitchell, Caroline Berube, Daniel A. Pollyea, S. E. Coutre, Leonel Gallegos, Richa Rajwanshi, Bruno C. Medeiros, Holbrook E Kohrt, Jason Gotlib
Publikováno v:
Journal of Clinical Oncology. 28:TPS280-TPS280
TPS280 Background: Induction therapy results in suboptimal outcomes in elderly AML patients (pts). CpG hypermethylation of tumor suppressor gene (TSG) promoters can reduce expression and contribute to these poor outcomes. Azacitidine (aza) prevents D